Dosing of Bedaquiline with Rifamycins reduces Rifabutin Plasma Concentrations

Main Article Content

Amanda M. Healan John Mcleod Griffiss Mary Ann O’Riordan Wesley A. Gray Robert A. Salata Jeffrey L. Blumerd


Bedaquiline (BDQ), a diarylquinoline mycobacterial ATP synthase inhibitor approved in the United States for drug-resistant tuberculosis, is metabolized by CYP3A4, an hepatic enzyme strongly induced by rifampin (RIF), an essential part of drug-sensitive tuberculosis treatment.  BDQ is used more broadly in some other countries and has been evaluated for treatment of non-tuberculosis mycobacterial infections, often in combination with rifabutin (RBT).  We examined the pharmacokinetic interactions of BDQ plus either RIF or RBT in 33 healthy volunteers.  Subjects were randomly assigned to receive two single 400 mg doses of BDQ, given 29 days apart, and either RBT 300 mg or RIF 600 mg, given daily from day 20 to 41 after the first dose of BDQ.  Blood samples were collected prior to dosing and at multiple subsequent time points to measure plasma drug concentrations, including those of the rifamycin primary metabolites.  BDQ treatment had little effect on the disposition of RIF but resulted in a dramatic shortening of the half-life of RBT and decreased exposure to it.  When the drugs were administered together (Day 29) the peak rifamycin concentrations and peak rifamycin metabolite concentrations were reduced significantly (p <0.001).  This appeared to result from reduced absorption and raises a concern that doses of BDQ and the rifamycins, particularly RBT should be staggered when the two drugs are given on the same day.  The optimum time between dosing should be determined.

Article Details

How to Cite
HEALAN, Amanda M. et al. Dosing of Bedaquiline with Rifamycins reduces Rifabutin Plasma Concentrations. Medical Research Archives, [S.l.], v. 10, n. 2, feb. 2022. ISSN 2375-1924. Available at: <>. Date accessed: 06 dec. 2022. doi:
Research Articles


Burman WJ, Gallicano K, Peloquin C. 2001. Comparative pharmacokinetics and pharmacodynamics of the rifamycin antibacterials. Clin Pharmacokinet, 40:327-341.
2. Williamson B, Dooley KE, Zhang Y, Back DJ, Owen A. 2013. Induction of influx and efflux transporters and cytochrome P450 3A4 in primary human hepatocytes by rifampin, rifabutin, and rifapentine. Antimicrob Agents Chemother. 57:6366-6369.
3 . Dooley KE, Sayre P, Borland J, Purdy E, Chen S, Song I, Peppercorn A, Everts S, Piscitelli S, Flexner C. 2013. Safety, tolerability, and pharmacokinetics of the HIV integrase inhibitor dolutegravir given twice daily with rifampin or once daily with rifabutin: results of a phase 1 study among healthy subjects. J Acquir Immune Defic Syndr. 62:21-27.
4. Lamorde M, Byakika-Kibwika P, Okaba-Kayom V, Ryan M, Coakley P, Boffito M, Namakula R, Kalemeera F, Colebunders R, Back D, Khoo S, Merry C. 2011. Nevirapine pharmacokinetics when initiated at 200 mg or 400 mg daily in HIV-1 and tuberculosis co-infected Ugandan adults on rifampicin. J Antimicrob Chemother. 66:180-183.
5. Matteelli A, Villani P, Carvalho AC, El-Hamad I, Cusato M, Apostoli A, Marcantoni C, Calabresi A, Dal Zoppo S, Bigoni S, Regazzi M. 2012. Lopinavir pharmacokinetic profiles in HIV-infected patients during rifabutin-based anti-mycobacterial therapy. J Antimicrob Chemother. 67:2470-2473.
6. Lan NT, Thu NT, Barrail-Tran A, Duc NH, Lan NN, Laureillard D, Thi Xuan Lien T, Borand L, Quillet C, Connolly C, Lagarde D, Pym A, Lienhardt C, Dung NH, Taburet AM, Harries AD. 2014. Randomised pharmacokinetic trial of rifabutin with lopinavir/ritonavir-antiretroviral therapy in patients with HIV-associated tuberculosis in Vietnam. PLoS ONE 9:e84866.
7. Philley JV, Wallace RJ Jr, Benwill JL, Taskar V, Brown-Elliott BA, Thakkar F, Aksamit TR, Griffith DE. 2015. Preliminary results of bedaquiline as salvage therapy for patients with nontuberculous mycobacterial lung disease. Chest 148:499-506.
8. Kwon YS, Koh WJ, Daley CL. 2019. Treatment of Mycobacterium avium complex pulmonary disease. Tuberc Respir DIS (Seoul) 82:15-26.
9. Lee J, Ammerman N, Agarwal A, Naji M, Li SY, Nuermberger E. 2021. Differential in vitro activities of individual drugs and bedaquiline-rifabutin combinations against actively multiplying and nutrient-starved Mycobacterium abscessus. Antimicrob Agents Chemother. 65:e02179-20. doi:10-1128/AAC.02179-20.
10. Liu K, Li F, Lu J, Liu S, Dorko K, Xie W, Ma X. 2014. Bedaquiline metabolism: enzymes and novel metabolites. Drug Metab Dispos. 42:863-866.
11. Healan AM, Griffiss JMcL, Proskin HM, O'Riordan MA, Gray WA, Salata RA, Blumer JL. 2018. Impact of rifabutin or rifampin on bedaquiline safety, tolerability, and pharmacokinetics assessed in a randomized clinical trial with healthy adult volunteers. Antimicrob Agents Chemother. 62:e00855-17.
12. Healan AM, Salata RA, Griffiss JMcL, Proskin HM, O’Riordan MA, Gray WA, Blumer JL. 2019. Effects of rifamycin coadministration on bedaquiline desmethylation in healthy adult volunteers. Clin Pharmacol Drug Dev. 8:436-442.
13. Gray WA, Waldorf B, Rao MG, Stiles BL, Griffiss JMcL, Salata RA, Blumer JL. 2019. Development and validation of an LC-MS/MS method for the simultaneous determination of bedaquiline and rifabutin in human plasma. J Pharm Biomed Anal. 176:112775. doi: 10.1016.
14. Blaschke TF, Skinner MH. 1996. The clinical pharmacokinetics of rifabutin. Clin Infect Dis. 22 Suppl 1:S15-21; discussion S21-12.
15. Kakuda TN, Woodfall B, De Marez T, Peeters M, Vandermeulen K, Aharchi F, Hoetelmans RM. 2014. Pharmacokinetic evaluation of the interaction between etravirine and rifabutin or clarithromycin in HIV-negative, healthy volunteers: results from two Phase 1 studies. J Antimicrob Chemother. 69:728-734.
16. Polk RE, Brophy DF, Israel DS, Patron R, Sadler BM, Chittick GE, Symonds WT, Lou Y, Kristoff D, Stein DS. 2001. Pharmacokinetic Interaction between amprenavir and rifabutin or rifampin in healthy males. Antimicrob Agents Chemother. 45:502-508.
17. Pfizer. Jan, 2010 posting date. Rifabutin (Mycobutin). [Online.]
18. Lannett Company I. March, 2013, posting date. Rifampin - rifampin capsule. [Online.]
19. Schmitt C, Riek M, Winters K, Schutz M, Grange S. 2009. Unexpected hepatotoxicity of rifampin and saquinavir/ritonavir in healthy male volunteers. Arch Drug Informat. 2:8- 16.
20. Greiner B, Eichelbaum M, Fritz P, Kreichgauer H-P, von Richter O, Zundler J, Kroemer HK. 1999. The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. J Clin Invest 104:147-153.
21. Finch CK, Chrisman CR, Baciewicz AM, Self TH. 2002. Rifampin and rifabutin drug interactions. Arch Int Med. 162:985-992.
22. Kwara A, Cao L, Yang H, Poethke P, Kurpewski J, Tashima KT,Mahjoub BD, Court Peloquin CA. 2014. Factors associated with variability in rifampin plasma pharmacokinetics and the relationship between rifampin concentrations and induction of efavirenz clearance. Pharmacother. 34:265-271.
23. Wallis RS, Good CE, O’Riordan MA, Blumer JL, Jacobs MR, Griffiss JMcL, Healan A,, Salata RA.
2018. Mycobactericidal activity of bedaquiline plus rifabutin or rifampin in ex vivo whole blood cultures of healthy volunteers: A randomized controlled trial. PLoS ONE 13:e0196756.